Health
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
PARIS, July 17, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of an exploratory analysis aimed at identifying predictive factors of the final best-corrected visual acuity (BCVA) in patients with Leber hereditary optic neuropathy (LHON) caused by a mu
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/ad4d77a52635f54322dd1bdac53c7337"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NrnI1A5KBVOEdpYiDJ32ag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ad4d77a52635f54322dd1bdac53c7337","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Better baseline visual acuity and thicker baseline optical coherence tomography (OCT) parameters predict better final visual outcome","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Patients treated during dynamic phase achieve better final visual outcome than those treated during subacute phase, which revises conventional wisdom on the best timing for gene therapy treatment","length":195,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"text","content":"PARIS, July 17, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of an exploratory analysis aimed at identifying predictive factors of the final best-corrected visual acuity (BCVA) in patients with Leber hereditary optic neuropathy (LHON) caused by a mutated mt-ND4 gene, all of whom were treated with LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON.","length":601,"tagName":"p"},{"type":"text","content":"The paper, published in the July 2025 issue of the journal Investigational Ophthalmology and Visual Science, a journal of ARVO (the Association for Research in Vision and Ophthalmology), concluded that "better baseline BCVA value and baseline thicker GCL (macular ganglion cell layer) and RNFL (retinal nerve fiber layer) are key predictors of the improved BCVA 1.5 years after treatment" among patients treated with LUMEVOQ® at least 6 months after disease onset. The authors performed univariate analyses on 113...